Clicky

Posts By :

Merci

Merci

Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who’ve Exhausted All Approved Therapies

440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / January 19, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief“), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the…

UMAX GROUP CORP. – Lowers Authorized Common Stock

150 150 Merci

LAS VEGAS, NV / ACCESSWIRE / January 5, 2022 / UMAX Group Corp. (OTC PINK:UMAX), a Nevada corporation, would like to announce that it has filed amended articles of incorporation with the State of Nevada,…

Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies

440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / January 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (“ Relief “), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need,…

Skeena Closes Strategic Investment from Franco-Nevada

210 93 Merci

VANCOUVER, BC / ACCESSWIRE / December 24, 2021 / Skeena Resources Limited (TSX:SKE)(NYSE:SKE) (“Skeena” or the “Company”) is pleased to announce that, on December 23, 2021, it closed the structured non-brokered private placement offering (the…

Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies

440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / December 30, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Relief“), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the…

Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir

440 386 Merci

GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) (“Relief“), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that…

NFT Mystery Box: Mint Block Technologies Introduces New Asset in the NFT Space

800 800 Merci

LOS ANGELES, CA / ACCESSWIRE / November 30, 2021 / Even though they are relatively new, NFTs are extremely popular, and every day, the popularity increases not only because the various blockchains represent DeFi (decentralized…

John Berberian of Atlanta Explains What to Expect From COVID-19 Testing

150 150 Merci

ATLANTA, GA / ACCESSWIRE / November 18, 2021 / COVID-19 testing is a relatively straightforward process that tends to only take a few minutes to complete. However, getting tested for COVID-19 can certainly be a…

SPYR Technologies Welcomes Trang Nguyen, CPA as Principal Financial Officer

150 50 Merci

GREENWOOD VILLAGE, CO / ACCESSWIRE / November 11, 2021 / SPYR, Inc. dba SPYR Technologies (OTCQB:SPYR), a technology company whose subsidiary Applied Magix, Inc. develops and resells Apple® ecosystem compatible products in the growing multi-billion-dollar…

MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

295 80 Merci

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A…